• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Mumbai, Jan. 25

Nicholas Piramal India Ltd (NPIL) has signed a research agreement with France’s Pierre Fabre Laboratories in the field of oncology. This was part of the framework of agreements formalised during the visit of French President Mr Nicolas Sarkozy to New Delhi.

The two pharmaceutical laboratories would collaborate on research on natural substances.

Pierre Fabre Group will provide expertise in screening and research in oncology, while NPIL will make available its natural products base, which will lead to the pharmacological characterisation of new molecules, NPIL said.

This agreement forms a part of the strategy of Pierre Fabre Laboratories to reinforce its presence in India and open new avenues of collaboration in the field of oncology research, which today represents 50 per cent of the research investments of the group. In India, marketing agreements have previously been signed with NPIL in 2004.

More Stories on : Alliances & Joint Ventures | Pharmaceuticals | Research & Development

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Degremont bags Rs 490-cr orders

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line